Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491739 | ||
| 003 | CHVBK | ||
| 005 | 20210128100511.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150401xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0799-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0799-2 | ||
| 245 | 0 | 0 | |a Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer |h [Elektronische Daten] |c [Shigehira Saji, Reiko Kimura-Tsuchiya] |
| 520 | 3 | |a Overcoming resistance to endocrine therapy is the most intensive research area in estrogen receptor (ER)-positive breast cancer. A strategy to restore endocrine sensitivity using molecular-targeted drugs such as mammalian target of rapamycin inhibitor everolimus along with endocrine therapy has already been used as a treatment option after the progression of previous aromatase inhibitor therapy. Phase II/III clinical trials of several signal pathway inhibitors and cyclin-dependent kinase 4/6 inhibitors are underway. In addition, a randomized phase II trial of the histone deacetylase inhibitor entinostat showed interesting findings. In this review, we summarize the mechanistic principles of combination therapy of molecular-targeted drugs with endocrine therapy by using a hybrid car model. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Estrogen receptor |2 nationallicence | |
| 690 | 7 | |a Molecular-targeted drugs |2 nationallicence | |
| 690 | 7 | |a Breast cancer |2 nationallicence | |
| 690 | 7 | |a Resistant |2 nationallicence | |
| 700 | 1 | |a Saji |D Shigehira |u Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, 960-1295, Fukushima, Fukushima, Japan |4 aut | |
| 700 | 1 | |a Kimura-Tsuchiya |D Reiko |u Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, 960-1295, Fukushima, Fukushima, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 268-272 |x 1341-9625 |q 20:2<268 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0799-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0799-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Saji |D Shigehira |u Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, 960-1295, Fukushima, Fukushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kimura-Tsuchiya |D Reiko |u Department of Medical Oncology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, 960-1295, Fukushima, Fukushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 268-272 |x 1341-9625 |q 20:2<268 |1 2015 |2 20 |o 10147 | ||